Germany · Delayed Price · Currency is EUR Relmada Therapeutics Company Description
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity.
It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease.
Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
| Country | United States |
| Founded | 2004 |
| Industry | Pharmaceutical Preparations |
| Employees | 17 |
| CEO | Sergio Traversa |
Contact Details
Address: 2222 Ponce de Leon Blvd. Coral Gables, Nevada 33134 United States | |
| Phone | 786 629 1376 |
| Website | relmada.com |
Stock Details
| Ticker Symbol | 4E2 |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sergio Traversa | Chief Executive Officer |
| Maged Shenouda | Chief Financial Officer |
| Paul Kelly | Chief Operating Officer |